Frequently Asked Questions

Clinicians considering prescribing antidepressants to their patients may utilize the BrightKaire™ blood test as a valuable tool to facilitate their decision-making process in finding the right drug for their patients.

Neurokaire's BrightKaire test for depression is currently commercially available. We are CE and CLIA certified and fully operational in the USA, Europe and Israel. If you or someone you know is struggling to find the right antidepressant and would like to benefit from Brightkaire™ visit www.neurokaire.typeform.com/BrightKaire

The BrightKaire™  test is a simple blood test that helps clinicians choose the best antidepressant medication for patients . The test uses a combination of neuronal imaging, genetic, and clinical data to predict how well a patient will respond to different antidepressants and how likely they are to experience side effects. Each patient and their clinician receives a detailed report on how their brain is likely to respond to an assay of 18 antidepressants and various other medications.

‍

The BrightKaire test is composed of two parts:

1. Genetic Testing

This part analyzes genes that affect how your body processes hundreds of different medications. It helps identify how efficiently you might metabolize certain drugs, which may help your provider choose a medication that works better for you.

‍

2. Neuroplasticity Testing

‍This part assesses how your neurons respond to specific medications in a lab environment, providing insight into your brain’s functional response. The medications evaluated include:

1. Selegiline
2. Mirtazapine
3. Trazodone
4. Vilazodone
5. Vortioxetine
6. Bupropion
7. Desvenlafaxine
8. Duloxetine
9. Venlafaxine
10. Citalopram
11. Escitalopram
12. Fluoxetine
13. Paroxetine
14. Sertraline
15. Amitriptyline
16. Nortriptyline

Together, these two components give a more comprehensive picture of how your body and brain may respond to certain antidepressants and related medications.

‍

‍

All of Neurokaire’s commercially available tests are run in CAP Accredited and CLIA Certified labs.

For U.S.-based clients:

Once your order is confirmed, we’ll automatically ship you a BrightKaire collection kit. Inside, you’ll find two blood tubes and a detailed instruction manual for the medical professional performing your blood draw.

You have two options for completing your blood collection:

1. Visit a Quest Diagnostics clinic – Bring your kit to your local Quest clinic, where a technician will draw your blood and handle shipping to our lab at no additional cost.
2. Schedule an at-home draw – For $60, you may book a licensed professional through TravelLabs to collect your sample from home.
   

Important: Blood draws must be done only on Monday, Tuesday, or Wednesday to prevent delays in shipping and avoid samples sitting idle over the weekend.

‍

For all other clients: Our team will contact you to organize blood procurement

‍

‍

‍

To get started visit Our link

NeuroKaire™ (formerly Genetika+) is a HIPAA (Health Insurance Portability and Accountability Act) covered entity. Results that contain protected health information will only be shared with the ordering physician and as otherwise permitted by law.

Your patient’s identifiable health information collected through Neurokaire™ is protected in accordance with HIPAA requirements and kept confidential. De-identified data from Neurokaire™ is used to improve the way mental health is diagnosed and treated. De-identified data may be used in research and in the development of new drugs, therapies, and analytical tools. NeuroKaire's™ (formerly Genetika+) notice of privacy practices is available here.

For biopharma partners who would like to speak to someone on our Biopharma Team or learn more about our portfolio for biopharma and research partners, please reach out to partnerships@neurokaire.com.

Preliminary results of BrightKaire's™ Pharmacogenetics test will be delivered to the ordering physician approximately 10-14 days from the time we receive the sample and order requisition form. Results for the final neuronal neuroplasticity score can take up to 8 weeks.

NeuroKaire combines our knowledge and experience into a dynamic platform which can be used to advance drug discovery. From target discovery to post marketing, NeuroKaire can be applied throughout the drug development lifecycle. We operate in parallel with your non-clinical or clinical processes to provide actionable results such as mechanistic insight and patient stratification.

The test is available for $995 USD.

We accept Health Savings Accounts (HSAs), Flexible Spending Accounts (FSAs), and are now working with Medicare and Medicaid for coverage in eligible U.S. states.

HMOs/private insurance may cover up to 70% of the cost in IL

Preliminary results of BrightKaire's™ Pharmacogenetics test will be delivered to the ordering physician approximately 15 business days from the time we receive the sample and order requisition form. Results for the final neuronal neuroplasticity score can take approximately 3 months. Our team is working diligently to decrease the time to results, please be patient as we are currently dealing with overwhelming demand.